2-ヒドロキシ-1,2,3-プロパントリカルボン酸/リチウム,(1:x)

Lithium Citrate

HCID 13520CAS 10377-38-5

部分構造検索類似構造を探す

基本情報

標準SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]
InChIKey: WJSIUCDMWSDDCE-UHFFFAOYSA-K
分子式: C6H5Li3O7
平均分子量: 210 g/mol
単同位体質量: 210.05154115

概要

Lithium Citrate can cause developmental toxicity according to state or federal government labeling requirements.

名称と識別子

優先名称: Lithium Citrate
IUPAC: trilithium;2-hydroxypropane-1,2,3-tricarboxylate
現地名: 2-ヒドロキシ-1,2,3-プロパントリカルボン酸/リチウム,(1:x)
英語名: citric acid, lithium salt
分子式: C6H5Li3O7
分子量: 209.9227

名称と別名

Lithium citrateLitarexCITRIC ACID, TRILITHIUM SALTLithium Citrate (anhydrous)anhydrous lithium citrateCHEBI:64735Lithium (as citrate)CHEBI:64754NSC-758700Li-liquidRefChem:55514trilithium(1+) 2-hydroxypropane-1,2,3-tricarboxylate

名称をさらに表示

2-ヒドロキシ-1,2,3-プロパントリカルボン酸/リチウム,(1:x)Einecs 233-819-9citric acid, lithium salt2-Hydroxy-1,2,3-propanetricarboxylic acid/lithium,(1:x) salt

5Z6E9K79YVLithonate S919-16-4Trilithium citrateCitric acid trilithium saltLithium citrate anhydrousLithium (Citrate)1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trilithium salt

データベース識別子

CAS: 10377-38-5、313222-91-2、6080-58-6、919-16-4
PubChem CID: 13520
DTXSID: DTXSID70883185
ChEMBL: CHEMBL1201170、CHEMBL2103738
ChEBI: CHEBI:64735
UNII: 3655633623
EC Number: 213-045-8、233-819-9、612-032-8、684-184-3
Nikkaji: J48.475J

物性

構造計算による物性

極性表面積: 141 Å²
水素結合供与体数: 1
水素結合受容体数: 7
回転可能結合数: 2
重原子数: 16
形式電荷: 0
複雑度: 211

実験および物理化学的性質

Chemical ClassesMetals -> Organic Acids, Metal Salts

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

Physical DescriptionTetrahydrate: White deliquescent solid; [Merck Index]

安全と法規制

GHS分類

GHS Classification · 6 件

Warning

H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

P264+P265, P280, P305+P351+P338, and P337+P317 (click each P-code to see the statement)

Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory.

This chemical does not meet GHS hazard criteria for 96.4% (27 of 28) of all reports.

Not Classified

危険有害性情報

Regulatory Information · 4 件

Chemical: 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trilithium salt

Hazard Traits - Developmental Toxicity

Status: Active Update: 23-05-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/22333

Lithium citrate: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trilithium salt: Human health tier I assessment

Hazards SummaryMay cause eye irritation; [GFS Chemicals MSDS] See Lithium.

Hazard Classes and Categories · 2 件

Not Classified

Eye Irrit. 2 (100%)

安全と保護具

Exposure Control and Personal Protection0.2 [mg/m3], inhalable fraction, as Li[German Research Foundation (DFG)]

毒性情報

Adverse EffectsNeurotoxin - Other CNS neurotoxin

化学と産業

薬理情報

Pharmacodynamics · 1 件

Although lithium has been used for over 50 years in treatment of bipolar disorder, the mechanism of action is still unknown. Lithium's therapeutic action may be due to a number of effects, ranging from inhibition of enzymes such as glycogen synthase kinase 3, inositol phosphatases, or modulation of glutamate receptors.

Mechanism of Action · 1 件

The precise mechanism of action of Li+ as a mood-stabilizing agent is currently unknown. It is possible that Li+ produces its effects by interacting with the transport of monovalent or divalent cations in neurons. An increasing number of scientists have come to the conclusion that the excitatory neurotransmitter glutamate is the key factor in understanding how lithium works. Lithium has been shown to change the inward and outward currents of glutamate receptors (especially GluR3), without a shift in reversal potential. Lithium has been found to exert a dual effect on glutamate receptors, acting to keep the amount of glutamate active between cells at a stable, healthy level, neither too much nor too little. It is postulated that too much glutamate in the space between neurons causes mania, and too little, depression. Another mechanism by which lithium might help to regulate mood include the non-competitive inhibition of an enzyme called inositol monophosphatase. Alternately lithium's action may be enhanced through the deactivation of the GSK-3B enzyme. The regulation of GSK-3B by lithium may affect the circadian clock. GSK-3 is known for phosphorylating and thus inactivating glycogen synthase. GSK-3B has also been implicated in the control of cellular response to damaged DNA. GSK-3 normally phosphorylates beta catenin, which leads to beta catenin degratation. When GSK-3 is inhibited, beta catenin increases and transgenic mice with overexpression of beta catenin express similar behaviour to mice treated with lithium. These results suggest that increase of beta catenin may be a possible pathway for the therapeutic action of lithium.

FDA Pharmacological Classification · 2 件

LITHIUM CITRATE

Mood Stabilizer [EPC]